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Countermeasures 
Outcomes 
Over the past twelve months, 58% (or 340) of patients requiring cervical ripening prior 
to induction of labor were managed with Cervidil. 401 doses were administered, at a 
cost of $2,214 per dose, for total charges of approximately $887,000.  Alternative 
methods for cervical ripening, often clinically appropriate, range from $2.73 to $180. 
Problem/Impact Statement: 
In scope (metric): Patients requiring cervical ripening for induction. Time frame from 
admission for induction to delivery. Out of scope: Not requiring ripening (dilated >6cm).   
In scope (intervention): Physicians and staff. Out of scope: Direct patient education.  
 
Scope: 
Decrease in Cervidil use for cervical ripening by 20% of anticipated doses prior to Dec 
1, 2018 (6 mos) , with a potential for cost savings = 40 doses x approx. $2000/dose = 
$80,000.  
 
Goal/Objective: 
Disparity in practice between seven practice groups with range in Cervidil use – ranging 
from 26% - 87% of cases. Range 50% to 4% use of very low risk, affordable mechanical 
ripening (balloon/foley).  
 Disparity examples: Use of 
 approaches by two groups: 
Baseline Metrics/Current State: 
• RCA based on survey of physicians, discussion with staff: 
   
• “5 Why” summary: 
        Discrepancy in Cervidil use between groups – Why? 
            Preferential use by some providers – Why? 
                Perceptions varied (re: cost, efficacy, staff required,  
                     weight given to convenience and comfort) – Why?  
                   Lack of education re: cost 
                   No local data reported 
                   Lack of standardized algorithm 
                   Need for clarity re: staffing required 
Root Cause Analysis: 
Next Steps 
Executive Sponsor: Zander Abbott MBA   
Facilitator: Deb Sepulveda MD MPH 
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• Practice feedback for Cervidil now 
integrated into Performance 
Improvement Committee 
• FY ’19 transformation focus on 
inductions  
• Algorithm posted on Obstetrical 
Guidelines webpage for access by 
other institutions   
$136,000 extrapolated “charge savings” over 4 months 
